Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant TQT study in healthy volunteers
NCT04795479Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Jan 2021
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of relacorilant in Cushing's syndrome (12 arms), sponsored by Corcept Therapeutics. Primary endpoint: Placebo-corrected Change from Baseline in Cardiac QT Interval Corrected by Fridericia's Formula. Started Jan 2021; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT04795479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795479.